Immune System News and Research

RSS

NIH scientists film early concussion damage and describe brain's response to injury

There is more than meets the eye following even a mild traumatic brain injury. While the brain may appear to be intact, new findings reported in Nature suggest that the brain's protective coverings may feel the brunt of the impact.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.

6 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

"Virtual T cell" predicts how human immune system reacts to foreign substances

A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

New research shows that the brain can produce and release estrogen

A University of Wisconsin-Madison research team reports today that the brain can produce and release estrogen - a discovery that may lead to a better understanding of hormonal changes observed from before birth throughout the entire aging process.

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Study reveals nearly 1 in every 100 anesthesiologist developed substance use disorder during training

According to a study conducted by Mayo Clinic and the American Board of Anesthesiology (ABA), nearly 1 in every 100 anesthesiology residents entering primary training from 1975 to 2009 developed substance use disorder (SUD) during training.

5 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

The first study of its kind, led by Melinda Sothern, PhD, CEP, Professor and Director of Behavioral and Community Health Sciences at LSU Health Sciences Center New Orleans School of Public Health, reveals that the same pro-inflammatory proteins linked to obesity and the metabolic syndrome in adults appear to protect children prior to puberty.

4 Dec 2013

Study focuses on effects of nanoparticles on eosinophils linked to inflammation

In a growing number of industries, workers are often unknowingly exposed to nanoparticles (NPs). Do they enter the body? Could they have an impact on health? Professor Denis Girard from the INRS-Institut Armand-Frappier Research Centre has had the foresight to study the potential toxicity of a wide variety of NPs with a view to setting the record straight before problems occur.

4 Dec 2013

1950s H2N2 avian influenza A virus still pose threat to human health

St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.

4 Dec 2013

UCI-led study results have important implications for HIV vaccine development

Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself. These results have important implications for HIV vaccine development and for understanding the earliest events in HIV transmission.

4 Dec 2013

Immune System News and Research

NIH scientists film early concussion damage and describe brain's response to injury

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Cancer triggers scleroderma, shows evidence

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

"Virtual T cell" predicts how human immune system reacts to foreign substances

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

New research shows that the brain can produce and release estrogen

IDSA released new guideline for vaccination of immunocompromised hosts

New method for counting tumor-fighting cells to predict ovarian cancer

Study reveals nearly 1 in every 100 anesthesiologist developed substance use disorder during training

TB vaccine may help prevent multiple sclerosis

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

Study focuses on effects of nanoparticles on eosinophils linked to inflammation

1950s H2N2 avian influenza A virus still pose threat to human health

UCI-led study results have important implications for HIV vaccine development

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News